Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer.

[1]  Andreas Sashegyi,et al.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial , 2014, The Lancet.

[2]  R. Kaiser,et al.  Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. , 2014, The Lancet. Oncology.

[3]  Yi Yin,et al.  Phosphatidylserine-Targeting Antibody Induces M1 Macrophage Polarization and Promotes Myeloid-Derived Suppressor Cell Differentiation , 2013, Cancer Immunology Research.

[4]  S. Knapp,et al.  Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[6]  M. Socinski,et al.  Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Neal,et al.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  H. Ohmatsu,et al.  Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy , 2012, BMC Cancer.

[9]  S. Nag,et al.  Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Ibrahim,et al.  Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors , 2011, Clinical Cancer Research.

[11]  P. LoRusso,et al.  Clinical development of vascular disrupting agents: what lessons can we learn from ASA404? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Nag,et al.  A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral Talactoferrin in Combination with Carboplatin and Paclitaxel in Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Yi Yin,et al.  Abstract 621: Targeting phosphatidylserine to improve androgen deprivation therapy of prostate cancer , 2011 .

[14]  P. D. de Groot,et al.  Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. , 2010, Blood.

[15]  J. Taube,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Shan,et al.  Phase II study of bavituximab plus paclitaxel and carboplatin in locally advanced or metastatic breast cancer: Interim results. , 2010 .

[17]  G. Nemsadze,et al.  Phase II study of bavituximab plus docetaxel in locally advanced or metastatic breast cancer. , 2010 .

[18]  F. Kabbinavar,et al.  Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): The FALCON trial. , 2010 .

[19]  G. Scagliotti,et al.  Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Horak,et al.  Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Ramlau,et al.  Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Jin He,et al.  Antiphosphatidylserine Antibody Combined with Irradiation Damages Tumor Blood Vessels and Induces Tumor Immunity in a Rat Model of Glioblastoma , 2009, Clinical Cancer Research.

[23]  R. Herbst,et al.  Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Seymour,et al.  Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Doval,et al.  Clinical Experience with Gefitinib in Indian Patients , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  P. Thorpe,et al.  Radiation-Enhanced Vascular Targeting of Human Lung Cancers in Mice with a Monoclonal Antibody That Binds Anionic Phospholipids , 2007, Clinical Cancer Research.

[27]  P. Dam,et al.  Phase II study of docetaxel, carboplatin and trastuzumab (THC) in patients with locally advanced breast cancer , 2007 .

[28]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[29]  P. D. de Groot,et al.  Plasma Protein β-2-Glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells* , 2006, Journal of Biological Chemistry.

[30]  R. Brekken,et al.  Combination of a monoclonal anti‐phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice , 2006, International journal of cancer.

[31]  Xin Li,et al.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Ran,et al.  Antitumor Effects of a Monoclonal Antibody that Binds Anionic Phospholipids on the Surface of Tumor Blood Vessels in Mice , 2005, Clinical Cancer Research.

[33]  T. Phan,et al.  Management of bleeding in patients with advanced cancer. , 2004, The oncologist.

[34]  U. Gatzemeier,et al.  Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) , 2004 .

[35]  F. Kabbinavar,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  G. Giaccone,et al.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Roy S Herbst,et al.  Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  A. Schroit,et al.  Aminophospholipid asymmetry: A matter of life and death. , 2003, Annual review of physiology.

[39]  S. Ran,et al.  Increased exposure of anionic phospholipids on the surface of tumor blood vessels. , 2002, Cancer research.

[40]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[41]  W. O'Fallon,et al.  Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. , 2000, Archives of internal medicine.

[42]  D. Behera,et al.  Clinical Spectrum Of Primary Lung Cancer-Review Of Chandigarh Experience Of 10 Years , 1990 .

[43]  L. Norton,et al.  Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a Cancer and Leukemia Group B Study. , 1989, The American journal of medicine.

[44]  K. O'Byrne,et al.  EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. , 2012, The Lancet. Oncology.

[45]  J. Levin,et al.  Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. , 1977, Medicine.